Kornimate/medical-research-clean huggingface dataset:
positive minds strong bodies implementation

Conditions: Depression; Anxiety; Physical Disability

Summary: this study aims to address treatment and service disparities and prevent disability among racial/ethnic and linguistic minority elders. it tests the effectiveness and implementation readiness of the positive minds-strong bodies enhanced intervention (pmsb-e), a combined mental and physical health intervention designed to be implemented in low-resource community settings. this renewal grant project includes a streamlined intervention with new components designed to improve and maintain participant outcomes.

the positive minds-strong bodies enhanced intervention addresses the dual challenges of mental health and physical disability among minority elders. the core positive minds intervention includes 10 sessions offered by community health workers over a maximum of 6 months, designed to identify and correct negative distortions or cognitions, promote behavioral activation and encourage supportive relationships. strong bodies is a 36-session physical intervention consisting of a series of exercises conducted while wearing a weighted vest in a group setting over 6 months; both interventions include a group maintenance component to maintain gains. the investigators will evaluate the acceptability, effectiveness and twelve-month sustainability of the enhanced positive minds-strong bodies intervention (e-pmsb) offered by community health workers (chws) and exercise trainers in community-based organizations (cbos) and community clinics. the intervention is offered in english, spanish, mandarin or cantonese.

Eligibility criteria:
inclusion criteria: * latino, asian, black, or non-latino white adults 60+ years of age * with mild, moderate or severe depressive or anxiety symptoms. * participants receiving medications for mental health will have this recorded and used as a covariate. * community-dwelling participants who have some mobility limitations but are not home-bound. exclusion criteria: * any specialty mental health care (therapy sessions with psychiatrist, psychologist or social worker) in the past 3 months or scheduled in the coming month. * evidence that patient lacks capacity to consent or is cognitively impaired * current suicidal risk (score of 4 or 5 on paykel suicide questionnaire), whereby participant will be connected to an emergency services or specialty provider per the study emergency protocol. * physically instability, acute or exacerbation of a chronic disease, or a neuro-musculoskeletal impairment * severe substance abuse * self-reported psychosis or schizophrenia * inability to commit to 2 sessions per week

Keywords: minority elders
efficacy and tolerability of abt-869 versus sorafenib in advanced hepatocellular carcinoma (hcc)

Conditions: Hepatocellular Carcinoma Non-resectable; Hepatocellular Carcinoma Recurrent; Carcinoma, Hepatocellular; Liver Diseases; Neoplasms by Histologic Type; Digestive System Neoplasms; Carcinoma; Liver Neoplasms; Neoplasms; Neoplasms by Site; Digestive System Diseases; Adenocarcinoma; Neoplasms, Glandular and Epithelial

Summary: the primary objective of this study is to assess the overall survival (os) of oral linifanib given as monotherapy once daily (qd) compared to sorafenib given twice daily (bid) per standard of care in subjects with advanced or metastatic hcc.

the idmc recommended discontinuation of the study, and, the protocol was amended to end study treatment.

Eligibility criteria:
inclusion criteria * histologic or cytologic diagnosis with unresectable or metastatic hcc * child pugh class a * ecog performance status 0-1 * adequate hematologic, hepatic, and renal function exclusion criteria * prior systemic (administered intravenously or orally rather than locoregionally) treatment for hcc * prior local therapy (including liver-directed therapy) within 4 weeks from entry * untreated brain or meningeal metastases * current treatment on another clinical trial * pregnancy or breastfeeding

Keywords: molecular mechanisms of pharmacological action antineoplastic agents growth substances physiological effects of drugs enzyme inhibitors angiogenesis inhibitors inhibitors, angiogenesis protein kinase inhibitors pharmacologic actions growth inhibitors angiogenesis modulating agents sorafenib
a new screening strategy for 2019 novel coronavirus infection

Conditions: Novel Coronavirus Infection Pneumonia

Summary: since dec 2019, over 70000 novel coronavirus infection pneumonia (ncip) patients were confirmed. 2019 novel coronavirus (2019 ncov) is a rna virus, which spread mainly from person-to-person contact. most of the symptoms are non-specific, including fever, fatigue, dry cough. sever ncip patients may have shortness of breath and dyspnea, and progress to acute respiratory distress syndrome (ards) and multiple organ dysfunction syndrome (mods). the mortality is reported to be around 2.3%. thus, early detection and early treatment is very important to the improvement of ncip patients' prognosis. at present, ncip rna detection of pharyngeal swab specimen by rt-pcr is recommended. however, due to the universal susceptibility to 2019 ncov in general population and limited number of ncip rna detection kits available, to identify an efficient screening strategy is urgently needed. this study aim to develop and validate the diagnostic accuracy and screening efficiency of a new ncip screening strategy, which can benefit the disease prevention and control.

this clinical trial is designed to compare the screen accuracy and efficiency of two screening strategies. considering that the general population is susceptible to 2019 ncov, a great number of people need to be screened for ncip. the new screening strategy of minipool testing may not only obtain a comparable accuracy to the standard individual testing, but also save time and money, which may benefit the current clinical practice.

Eligibility criteria:
inclusion criteria: * who agree to participate in the study and sign written informed consent exclusion criteria: * confirmed ncip patients
phase ii study , association of cisplatine topotecan and cetuximab in patients whith late or in progress epithelial cancer of the cervix

Conditions: Cervix Cancer

Summary: the efficacy of chimiotherapy in cervix epithelial cancer is low even with the association cisplatine - topotecan . news thérapeutics are needed in the goal of increase the survival and quality of life in patients with cervix cancer. cetuximab has shown the potentialisation on the efficacy of cisplatine and irinotecan. cisplatine and topotecan have shown an efficacy in cervix cancer. cetuximab is well tolerate. many clinical trials shown the faisability of the association of cetuximab and cisplatine in cancer. many clinical trials have shown the faisability of association of cetuximab and irinotecan in colorectals metastatiques cancers .


Eligibility criteria:
inclusion criteria: * more than 18 years old. * epidermoïde carcinoma or adenocarcinoma of the cervix, hystologic proved * patientes in a late stage or with progresive desease. * one mesurable lesion in irradiated zone. * patient who have already treated radio-chimiothérapy with platine should have a 6 month free interval. * index status of ecog (" eastern cooperative oncology group ")less than 2. * good biologicals and hematologicals fonctions: * neutrophiles noless than 1,5.109/l. * platelets nolss than 100.109/l. * total bilirubin no more than 1,5 time the normal superior range. * transaminases no mote than 3 x time nsr * creatinine clairance cockroft) more than 50 ml/min . * inform consent signed. exclusion criteria: * previous cytotoxic traitement exept radio-chaemiotherapy of the pelvis cerebrals metastasis. * other cancer in the last 5 years exept treated bcc. * dermatologic desease. * crohn desease or hemorragic rectal-colitis. * neuropathy. * psychologic disorder. * social troubles. * pregnant women.
effect of endometrial injury in couples with unexplained infertility

Conditions: Unexplained Infertility

Summary: 100 patient of unexplained infertility recruited and divided into two groups for the study group (50) endometrial scratching done in preovulatory period after controlled ovarian stimulation by clomiphene citrate , then followed and compared to control group for 6 months to asses pregnancy rate

induction of ovulation was done by clomophine citrate (selective estrogen modulator of triphenylethylene group, produced by( sanafi aventis company) from 3rd day of cycle till 7th day of cycle and hmg 75iu (merional) produced by ibsa ( institute biochimique sa) given from 6th day of cycle till 8th of cycle once daily. folliculometry done regularly during induction of ovulation till dominant follicle reached 18_20mm in size. then endometrial injury performed in pre ovulatory day by a thin pipelle (a fine, flexible, sterile, plastic tube) produced by jiangsu guard king medical equipment co. the procedure was carried out in preovulatory day (known when dominant follicle reached 18_20 mm in diameter), usually, done around day 14-day of the cycle. in the theatre, patients put in a lithotomy position, sterilization was performed with the presence of good source of light., the procedure was carried out using a thin pipelle tube as follow :- a cuscoe's speculum was inserted into the vagina in order to visualize the cervix. cervix was grasped by vollselum upwards backwards, then pipelle tube passed through the cervix and uterine cavity, then moved up and down to make a single induced scratch two times in the lining endometrium of posterior wall of uterus. the procedure took approximately 15minutes to complete. it was uncomfortable or painful in some circumstances and that bleeding after the procedure happened in many cases. post procedure antibiotics were given. couples were advised to practice timed sexual intercourse for next 6months and couples in both groups were asked to phone a contact person whenever there was a missed period. the patients followed up for six months for detecion of the biochemical pregnancy if occurred. 2- control group (50patients) :- they received the same induction of ovulation as first group but without performing endometrial injury in preovulatory day. we wait till time of period if missed period achieved serum pregnancy test done after one week of missed period . all women followed for 6 months after treatment. comparative study was done for both groups and results presented in tables and statistically analyzed

Eligibility criteria:
inclusion criteria: * unexplained infertility ( 1ry \& 2ndry infertility) : \* * normal hormonal profile of infertile woman. * normal hystrosalpingogram. * normal laparoscopy. * normal investigation of the cervical factor * fertile semen analysis (according to world health organization criteria 2015). exclusion criteria: * • infertile semen analysis. * abnormal hsg. * abnormal laparoscopic findings. * disturbed hormonal profile. * evidence of cervical factor. * known genetic disorder * known autoimmune disease
erector spinae vs tap in lower abdominal surgery

Conditions: Postoperative Pain

Summary: the aim of this study is to compare the analgesic effect and safety profile of erector spinae plane block with transverses abdominis plane block in controlling peri-operative pain for lower abdominal cancer surgery.

pain triggers a complex biochemical and physiological stress response leading to impairment of pulmonary, immunological and metabolic functions. opioids are the current gold standard drug for postoperative pain relief, however exposure to large doses lead to multiple side effects of varying significance such as nausea, vomiting, dizziness, constipation, respiratory depression, hypoventilation and sleep breathing disorders. therefore strategies other than opioids are recommended without sacrificing proper and effective analgesia. especially in cancer patients who are more susceptible to tolerance and addiction. the transversus abdominis plane (tap) block, is a regional anaesthesia technique used effectively in laparotomies. unilateral analgesia to the skin, muscles, and parietal peritoneum of the anterior abdominal wall will be achieved without affecting visceral pain, when the anterior rami of the lower six thoracic nerves (t7-t12) and the first lumbar nerve (l1) are blocked. erector spinae plane block (espb) was shown to be an effective analgesic option for different types of surgeries. it's relatively a simple block, drug is injected in the plane between the erector spinae muscle and the vertebral transverse process. blocking the ventral and dorsal rami of spinal nerves on the paravertebral area distributed from t2-t4 to l1-l2 and gives good coverage to visceral pain. owing to the lower risk of blood vessel damage and neural damage compared to the epidural or the paravertebral block. both blocks haven't been compared to each other in this type of surgery before.

Eligibility criteria:
inclusion criteria: * physical status asa ii. * age ≥ 18 and ≤ 65 years. * cancer patients undergoing laparotomies for radical cystectomy or radical hysterectomy or low anterior resection (lower abdominal procedures). * patient is able to provide a written informed consent. * body mass index (bmi): \> 20 kg/m2 and \< 40 kg/m2. exclusion criteria: * age \ 65 years. * bmi \ 40 kg/m2. * known sensitivity to local anaesthetics and morphine. * history of psychological disorders and/or chronic pain. * significant liver or renal insufficiency. * contraindication to regional anaesthesia e.g. local sepsis, preexisting peripheral neuropathies and coagulopathy. * patient refusal. * severe respiratory or cardiac disorders. * pregnancy. * asa iii-iv.

Keywords: erector spinae block tap block abdominal surgery
the assessment of knee joints function in people after stroke

Conditions: Stroke

Summary: the study aims to assess the function of knee joints in patients after stroke compared to healthy people and evaluate the impact of rehabilitation on the function of knee joints in people after stroke.

stroke patients were examined twice at the beginning of rehabilitation and after approximately 15 days of exercise. the control group (healthy participants) was assessed once. wireless motion sensors connected to a mobile application were used to assess the kinematics of the knee joints. they were used to assess the range of motion in the knee joints (passive, active, active at maximum speed), proprioception (joint position sense tests), step-up test, step-down test, getting up and sitting on a chair, step and squat. functional tests such as the five times sit-to-stand test, timed up\&go, the step test, the 5m walking test, and the 30-s chair stand test were carried out. the strength of the knee extensors and flexors was also assessed using the leg force feedback device. balance was assessed on a posturography platform by performing tests such as standing with eyes open and closed on a stable surface and standing with eyes open and closed on an unstable surface. the symmetry of lower limb loads in a standing position was also assessed.

Eligibility criteria:
inclusion criteria to the stroke group were as follows : * the time from stroke: less than a year, * age: between 35 and 65 years old, * ability to stand independently for at least 5 minutes without an assistive device, * ability to walk 5 m independently, * ability to communicate and understand the tasks required in the study, * a modified ashworth scale spasticity score of 1+ or less in the affected knee (0: no resistance, 5: affected parts stiff in flexion or extension), * muscle strength on the manual muscle test of 3/4 or more in the affected knee, * barthel index score 80 or more. exclusion criteria from the post-stroke group were as follows: * age below 35 or over 65, * sensorimotor aphasia, * cognitive disorders that make it impossible to understand and obey commands, * lack of active movement in the knee joint, * manual muscle test strength of the quadriceps muscles below 3, * no ability to walk 5 meters, * lack of informed consent to participate in the study, * other neurological diseases (such as ms, parkinson's disease, neuropathies), * fractures in the lower limbs, which could affect the structure and function of the knee joint, * previous operations on the lower limbs (including acl reconstruction, knee arthroplasty or hip, osteotomy of the knee joint). * vision disorders, * unilateral spatial neglect syndrome. the control group consisted of healthy volunteers with no prior history of trauma or neurological disease affecting the structure and function of the lower limb.

Keywords: function of knee joint physiotherapy wireless sensors functional tests
refine-hcm: intramyocardial septal radiofrequency ablation for obstructive hypertrophic cardiomyopathy

Conditions: Hypertrophic Cardiomyopathy, Obstructive

Summary: this is a prospective, multicenter, randomized, parallel-controlled, superiority clinical trial designed to evaluate the efficacy and safety of a transcatheter intramyocardial septal radiofrequency ablation system for the treatment of patients with obstructive hypertrophic cardiomyopathy (ohcm). eligible participants will be randomized in a 2:1 ratio to receive either active ablation under intracardiac echocardiographic guidance or a sham procedure. all participants will continue to receive standard-of-care medical therapy during the study period. the primary endpoint is the treatment effectiveness rate at 6 months, defined as a ≥50% reduction in lvot gradient from baseline or a resting lvot gradient \<30 mmhg.


Eligibility criteria:
inclusion criteria: * age 18 to 80 years, regardless of sex * diagnosed with obstructive hypertrophic cardiomyopathy (ohcm) * presence of significant symptoms (e.g., dyspnea, chest pain, fatigue, palpitations, syncope) * nyha class ii or higher with lvotg ≥50 mmhg at rest or provoked (assessed by echocardiography) * septal thickness ≥15 mm * unsuitable for surgical myectomy or refusal of surgery * provided informed consent and agree to complete follow-up exclusion criteria: * asymptomatic or non-obstructive hcm * septal thickness ≥30 mm * mitral valve anatomy not suitable for ablation as judged by investigator * high risk of sudden cardiac death (scd) requiring icd implantation * complete right bundle branch block at screening * infective endocarditis, myocarditis, atrial myxoma, or intracardiac thrombus * contraindication to transseptal access (e.g., septal patch) * mechanical valves or history of aortic valve replacement * severe heart failure with persistent symptoms and lvef \<40% * major cardiac events within 6 months (e.g., cardiac arrest, mi, heart failure hospitalization) * significant structural heart disease requiring surgery * prior septal reduction therapy or pacemaker implantation * constrictive pericarditis or significant congenital heart disease * bleeding disorders or contraindication to antithrombotic therapy * liver dysfunction (alt/ast \>3× uln) * renal insufficiency (creatinine \>2.0 mg/dl or on dialysis) * pregnant, breastfeeding, or planning pregnancy within 6 months post-op * life expectancy \<12 months * participation in other investigational studies within 30 days or 5 half-lives * investigator determines poor compliance or unsuitability * contraindications to cardiac mri (e.g., icd, allergy to contrast, claustrophobia)
analysis of mirnas expression in vasoplegic syndrome after on-pump coronary artery bypass surgery

Conditions: Vasoplegic Syndrome; Vasoplegia; Surgery-Complications; Surgery; Cardiovascular Diseases; Cardiovascular Morbidity

Summary: this study looks for a correlation between micrornas (mirnas) and vasoplegic syndrome after on-pump coronary artery bypass surgery.

cardiovascular diseases (cvd) are among the main causes of morbidity and mortality in the world, and in brazil they account for approximately 31% of all causes of death and 42% of deaths due to noncommunicable diseases. in 2014 were carried out a total number of 92,000 heart surgeries in brazil and these are usually performed using cardiopulmonary bypass (cpb), which is made by the diversion of blood circulation of the lungs and heart to a heart-lung machine, which keeps cardio circulatory functions and oxygenates the blood. despite enable various types of major cardiac surgery, the use of cpb can cause serious side effects such as post perfusion vasoplegic syndrome (vs). this is characterized by increased cardiac output, hypotension, systemic inflammatory response and decreased vascular resistance, affecting 9-44% of patients in the postoperative period of cardiac surgery, with a mortality of 27%. treatment to vs are limited and the drugs are often ineffective, including noradrenaline, vasopressin, and methylene blue. another difficulty encountered by the surgeon is to establish a predictive factor for vs. systems risk predictors that use score and are well validated as euroscore (european system for cardiac operative risk evaluation) have not been tested for vs. much has been studied on the use of biomarkers as predictors and for prognosis as well as to improve predictive power of the rating systems available. micrornas (mirnas) are noncoding rna molecules that control gene expression in the intracellular environment and are present circulating in various body fluids including peripheral blood. these molecules can be used as biomarkers of various pathologies including cvd. despite the existence of numerous studies that demonstrate the importance of mirnas in the development of cvds. there are no studies that address the issue in vs. therefore, the objective of the project is to identify the presence of blood mirnas that are altered in patients with pre and intra-operative cardiovascular surgery and assess whether these mirnas can be used as predictors and biomarkers of mortality for vs.

Eligibility criteria:
inclusion criteria: * patients who go to coronary artery by-pass , on-pump surgery * patients who sign an informed consent * only elective or urgency surgery exclusion criteria: * off-pump surgery * emergency surgery * previous use of vasoactive drugs or intra aortic balloon * patients with active acute coronary syndrome * acute mesenteric ischemia, reynaud disease, neoplasia and pregnancy

Keywords: vasoplegic syndrome vasoplegic surgery cardiovascular micrornas mirnas